Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Corroborated by 1 source from 1 publisher
globalhealth5h ago
TL;DR
According to finance.yahoo.com, quick Read - - Barclays expects strong prescription volume growth through 2026 as VOQUEZNA gains traction in GERD and H.